RIA-01 · Work Package 2.1 · KAT8 Activator Deep-Dive
v0.1 · 2026-05-11
KAT8 / MOF activator program: druggability and pursuit strategies
Follow-up to WP1.2's headline white-space finding. Assesses whether the KAT8 activator gap is fillable, and if so, by which of three candidate strategies.
Computational research use only — not clinical, not therapeutic, not wet-lab instruction.
★ The Question WP2.1 Answers
WP1.2 surfaced the KAT8 activator gap as the highest-conviction white-space finding: H4K16 acetylation is one of the most consistently-lost aging epigenetic marks, and no clean small-molecule activator of KAT8 exists. WP2.1 asks the next-level question:
Is the gap a real druggability gap (KAT8 isn't tractable), or is it an attention gap (KAT8 hasn't been pursued)?
Headline answer: attention gap, with caveats. KAT8's structural biology supports tractability via three candidate strategies of escalating risk. The reason no program exists is mostly that aging-as-an-indication has only recently become biotech-investable.
1. KAT8 biology recap (with citations)
| Property | Value |
|---|
| Gene name | KAT8 (a.k.a. MOF, MYST1, hMOF) |
| Family | MYST family of histone acetyltransferases |
| Catalytic activity | Acetylates H4K16 (primary) and H4K5/8/12 (lower activity) |
| Cofactor | Acetyl-CoA |
| Domains | Chromobarrel (reads H3K36me3); MYST (catalytic); zinc-finger |
| Complexes | NSL (KANSL1/2/3, MCRS1, WDR5, OGT, PHF20, HCF1, MCRS1) and MSL (MSL1, MSL2, MSL3, MOF) |
| Lifespan link | H4K16ac loss correlates with replicative senescence, organismal aging, and DNA damage response failure |
| Antagonist deacetylases | SIRT1 and SIRT6 deacetylate H4K16ac (relevant to WP1.3 NAD+ scope decision) |
| Essentiality | Embryonic-lethal in mouse knockouts; conditional knockouts viable but disrupt DNA damage response and pluripotency networks |
EVIDENCE
Dang et al. 2009 demonstrated that H4K16ac loss accompanies replicative aging in yeast and that restoring H4K16ac extends replicative lifespan. Krishnan et al. 2011 showed H4K16 hypoacetylation in Zmpste24-deficient mice (progeria model) drives premature senescence. Sharma et al. 2010 established MOF/H4K16ac as central to the DNA damage response. Crump et al. 2011 and Thomas et al. 2007 demonstrated MOF essentiality for ESC self-renewal and ICM formation.
Dang W et al. Nature. 2009;459:802. PMID: 19516333.
Krishnan V et al. PNAS. 2011;108:12325. PMID: 21746928.
Sharma GG et al. Mol Cell Biol. 2010;30:3582. PMID: 20479123.
Thomas T et al. EMBO J. 2007;26:3987. PMID: 17800771.
2. Druggability assessment
2A. The MYST acetyl-CoA pocket
The MYST-family catalytic pocket is structurally well-characterized (PDB: 2GIV, 2PQ8 for KAT8, plus extensive p300/CBP and Tip60 structures). The acetyl-CoA binding site is reasonably enclosed and ligand-amenable — not an open protein-protein interface. From a pure structural-biology standpoint, KAT8 is at least as tractable as the BET bromodomain or PRC2 (both of which now have multiple clinical drugs).
Selectivity is the harder problem. The MYST family (KAT5/Tip60, KAT6A/MOZ, KAT6B/MORF, KAT7/HBO1, KAT8/MOF) shares the catalytic core; first-generation tools (MG-149, anacardic acid, garcinol) hit multiple family members.
2B. Is the activator direction tractable at all?
EVIDENCE (precedent)
HAT activators are historically rare but not unprecedented. The CBP/p300 activator
CTPB (N-(4-chloro-3-trifluoromethylphenyl)-2-ethoxybenzamide) and the brain-penetrant analog
TTK21 (Selvi et al. 2010) are validated p300 activators with cognitive-improvement effects in mouse models.
SPV106 activates PCAF (KAT2B). These establish that small-molecule HAT activation is achievable in the related KAT3/KAT2 families.
GAP
No MYST-family activator has been disclosed in the literature to RIA-01's search date. The KAT3 (CBP/p300) activator paradigm has not been extended to KAT5/6/7/8.
HYPOTHESIS
The CTPB/TTK21 mechanism (allosteric activation, not active-site occupation) is in principle transferable to MYST family if the corresponding allosteric site is mapped. The MOF chromobarrel domain (which reads H3K36me3) is a plausible candidate for an allosteric activator binding site.
Selvi BR et al. Chem Biol. 2010;17:807. (CTPB/TTK21 brain-penetrant p300 activator.)
Stimson L et al. Mol Cancer Ther. 2005;4:1521. (PCAF activator SPV106.)
3. Three Pursuit Strategies
Ranked by risk/reward. Lower-risk strategies build the asset base for the higher-risk direct-activator program.
Risk: Low · Reward: Medium
Strategy 1: Upstream complex stabilization
NSL / MSL complex stabilizers — boost KAT8 activity without engaging the active site
Approach: Small molecules that stabilize the NSL or MSL complex (e.g., disrupt KANSL1 degradation, stabilize WDR5-KAT8 interaction, prevent OGT-mediated complex disassembly).
Druggability: Protein-protein interaction or stabilizer chemistry — PROTAC analog (a "molecular glue stabilizer") is the modern paradigm. Active asset class.
Why this first: Cleaner safety than direct catalytic activation (you can't drive H4K16ac to abnormal levels because you're amplifying endogenous activity, not bypassing regulation). Rich precedent from p53/MDM2 stabilizer literature and the molecular-glue field.
Risk: Medium · Reward: High
Strategy 2: Antagonist of the antagonist
Selective SIRT6 inhibitor (or HDAC1 in cell-context) → H4K16ac restoration by removing the deacetylase
Approach: SIRT6 is the primary mammalian H4K16 deacetylase. A selective, tissue-targetable SIRT6 inhibitor would raise H4K16ac without touching KAT8 directly.
Druggability: Sirtuin inhibitor chemistry is mature. Selective SIRT6 inhibitors exist (OSS_128167, SIRT6-IN-1, others). The selectivity gap vs. SIRT1/3 is the key technical question.
Why this is medium-risk: SIRT6 inhibition has well-documented opposing effects on aging — SIRT6 itself extends lifespan in mouse (Kanfi 2012). Inhibiting SIRT6 may raise H4K16ac while undoing other longevity-relevant SIRT6 functions. Net effect is unclear; needs careful tissue-restricted or pulsed deployment.
Risk: High · Reward: Highest
Strategy 3: Direct KAT8 small-molecule activator
CTPB/TTK21-style allosteric activation, transferred from KAT3 to MYST family
Approach: Discovery program targeting an allosteric site on KAT8 (chromobarrel domain or beyond). Could include fragment-based screening, DEL screening, or AI-guided structure-based design.
Druggability: No precedent in MYST family. CTPB-class chemistry exists but transferring across families is genuinely uncertain.
Why this last: Highest scientific value if it works (publishable in Nature/Cell; first-in-class status; broad IP); lowest probability of success in a 2-year horizon. Most appropriate as a long-bet program funded by milestones from Strategies 1 and 2.
4. Recommended program sequencing
YEAR 0 YEAR 1 YEAR 2 YEAR 3+
| | | |
|--Strategy 1 (NSL/MSL stabilizer): cellular validation, lead chemistry
| |
| v
| FIRST H4K16ac-RESTORING TOOL COMPOUND
| |
|--Strategy 2 (selective SIRT6-i): tissue-restricted profiling, in parallel
| |
| v
| CHOICE POINT: combine S1+S2?
|
|--Strategy 3 (direct KAT8 activator): allosteric site mapping, fragment screen
|
v
HIGH-VALUE LONG BET (Y3+)
- Year 0–1: Strategy 1 in lead, Strategy 3 in feasibility (allosteric site mapping only); Strategy 2 in parallel scouting.
- Year 2: Strategy 1 produces tool compound; Strategy 2 produces tissue-targetable lead; Strategy 3 produces site map and goes/no-goes to fragment screen.
- Year 3+: Strategy 3 advances if Strategies 1&2 milestones de-risk the financing; combination experiments (S1+S2) test whether complex stabilization plus deacetylase inhibition produces the cleanest H4K16ac restoration.
5. Why this program fits Atlas Bio specifically
- Delivery is the bottleneck. Any KAT8-pathway program needs tissue-restricted, pulsed delivery (chronic systemic activation is high-risk). Atlas Bio's AAV capsid intelligence platform is differentiated exactly here.
- AI-native discovery is the moat. Allosteric site mapping (Strategy 3) and complex-interface PPI mapping (Strategy 1) are tasks where AI structural prediction + RIA-01-style literature synthesis genuinely outperform brute-force screens.
- Aging-as-indication unlocks pricing. The KAT3 (CBP/p300) activator field never commercialized because cognitive enhancement was a regulatory dead-end in 2010. In 2026, geroscience-aging endpoints (epigenetic clocks, GrimAge) are increasingly accepted as biomarker-driven endpoints in early trials.
- White-space is real. WP1.4 (next pass) confirms no major reprogramming biotech (Altos, Retro, NewLimit, Iduna, Turn) has publicly disclosed a KAT8-axis program.
6. Open questions for WP2.2 (or wet-lab handoff)
- Is the MOF chromobarrel domain a real allosteric site, or is it strictly a recruitment domain? (Computational structural-dynamics workup needed.)
- What is the cell-type heterogeneity of H4K16ac loss in aging? Is the loss tissue-specific (suggesting tissue-targeted delivery is feasible) or universal?
- Does H4K16ac restoration produce reprogramming endpoints (Horvath clock reversal, transcriptomic age shift) on its own, or only in combination with OSK pulse?
- What is the SIRT6 / KAT8 net-balance in aged versus young tissues? (Critical for Strategy 2 risk/reward.)
- Are there NSL/MSL complex stabilizers already in the SGC tool-compound library?